Economics evaluation of alendronate versus ibandronate for postmenopausal osteoporosis in local community hospitals.

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: HUANG, Hsiao-Feng (Chi Mei Hospital, Chiali, Tainan, China Taiwan)
  • Co-author(s): Hsiao-Feng Huang
  • Abstract:


    We undertook a retrospective review of patients with postmenopausal women were receiving into one of two treatment arms: quarterly i.v. administration of 3 mg ibandronate or weekly oral medication of 70 mg alendronate for 12 months at the local community hospitals from 2013 through 2016. The endpoints of study were efficacy, side effect and ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login